# Angels Santé

> Angels Santé is a VC fund in Puteaux backing Health Care and Biotechnology. See 37 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Puteaux, France
- Total investments: 37
- Last investment: Dec 2025
- Lead investor: 11%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/search/results/all/?heroEntityKey=urn%3Ali%3Aorganization%3A12666394&keywords=Angels%20Sant%C3%A9&origin=ENTITY_SEARCH_HOME_HISTORY&sid=piU
- Website: https://www.angelssante.fr/en/

Angels Santé is a VC fund in Puteaux focused on Health Care and Biotechnology. Angels Santé is the leading French Business Angel Network solely dedicated to Healthcare investments.

## Contacts

5 contacts available for Angels Santé. Shizune tracks 4 team members at Angels Santé. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/angels-sant?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.1M–$4.6M |
| Angel | $658k–$1.3M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 15 | 41% |
| Biotechnology | 12 | 32% |
| Medical Device | 6 | 16% |
| Medical | 5 | 14% |
| Life Science | 4 | 11% |

35 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 22 | 59% |
| Funding Round | 4 | 11% |
| Angel | 2 | 5% |
| Pre-Seed | 2 | 5% |
| Series A | 2 | 5% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 28 | 76% |
| India | 1 | 3% |
| United States | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Guy-Charles Fanneau de la Horie | Co-founder | 0 | https://shizune.co/investors/profile/guy-charles-fanneau-de-la-horie-e1b6 |
| Patrick squiban | Executive | 1 | https://shizune.co/investors/profile/patrick-squiban |
| Pierre-Emmanuel Aubert | Co-Founder and member of the board | 0 | https://shizune.co/investors/profile/pierre-emmanuel-aubert |
| Stéphane Loze | Administrator – Partnerships Manager – Treasurer | 1 | https://shizune.co/investors/profile/st%C3%A9phane-loze |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kimialys | Kimialys develops and sells proprietary and patented surface chemistry for biosensors, increasing their sensitivity and specificity to deliver reliable, rapid, and cost-effective diagnostic tests. It was founded in 2020 by Cyril Gilbert and Claude Nogues in Paris, Ile-de-France, France. | $4.2M | Seed | Dec 05, 2025 |  |
| SeaBeLife | SeaBeLife is a biotechnology company that develops a range of drug candidates intended to block regulated necrosis (or regulated cell death of cells), from a family of patented molecules. | $2.3M | Seed | Oct 01, 2025 |  |
| StemInov | StemInov is a biotechnology company that focuses on the development of stem cell therapies for inflammatory diseases. The company's primary focus is on critical care, specifically septic shock and Acute Respiratory Distress Syndrome (ARDS). StemInov's approach is based on robust preclinical data and widely accepted safety measures. Thecompany is developing an off-the-shelf and allogenic cell therapy. StemInov is also working on a drug-based therapy using mesenchymatous stem cells from Wharton's jelly (WJ-MSC). | $12.4M | Series A | Sep 25, 2025 |  |
| AUSTRAL Dx | AUSTRAL Dx is developing a new imaging technique based on airborne ultrasounds in order to map the vibrations coming from the lungs. The company was founded in 2021 and is based in Paris. | $1.1M | Seed | Jul 24, 2025 |  |
| Ensweet | Ensweet is a telemedicine platform intended to offer telerehabilitation services to patients. They offer equipment so that everyone can exercise whenever possible, enabling patients to have accessible rehabilitation. | $3.4M | Seed | May 20, 2025 |  |
| MB Therapeutics | MB Therapeutics is a pharmaceutical firm that provides patient-centric solutions for developing and producing tailored medicines. | $2.1M | Seed | Feb 24, 2025 |  |
| Sirius NeoSight | Sirius NeoSight is a biotech and pharmaceutical company that detects subclinical neo-cancers and provide treatment for it. | $4.6M | Seed | Feb 04, 2025 |  |
| HEPHAISTOS-Pharma | Hephaistos Pharma is a developing weapons firm. They provide services for oncology, immunotherapy, and cancer. An online inquiry form is available on the company's website. | $4.9M | Seed | Jan 23, 2024 |  |
| SeaBeLife | SeaBeLife is a biotechnology company that develops a range of drug candidates intended to block regulated necrosis (or regulated cell death of cells), from a family of patented molecules. | $1.3M | Seed | Sep 26, 2023 |  |
| Abcely | Abcely is a biotech firm that is working on a novel anti-cancer medication. | $2.6M | Seed | Sep 21, 2023 |  |

10 of 37 investments shown.

## Co-investors
- [Femmes Business Angels](https://shizune.co/investors/profile/femmes-business-angels) — VC Fund, 9 deals together
- [Les Business Angels des Grandes Écoles](https://shizune.co/investors/profile/les-business-angels-des-grandes-%C3%A9coles) — VC Fund, 9 deals together
- [Paris Business Angels](https://shizune.co/investors/profile/paris-business-angels) — VC Fund, 9 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 8 deals together
- [Business Angels des Grandes Ecoles](https://shizune.co/investors/profile/business-angels-des-grandes-ecoles) — VC Fund, 7 deals together
- [50 Partners](https://shizune.co/investors/profile/50-partners) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Kima Ventures](https://shizune.co/investors/profile/kima-ventures) — VC Fund
- [Motier Ventures](https://shizune.co/investors/profile/motier-ventures) — VC Fund

## Featured in investor lists
- [Health Care Investors in France](https://shizune.co/investors/health-care-investors-france)
- [Health Care VC Funds in France](https://shizune.co/investors/health-care-vc-funds-france)
- [Health Care Investors in Europe](https://shizune.co/investors/health-care-investors-europe)
- [Health Care VC Funds in Europe](https://shizune.co/investors/health-care-vc-funds-europe)
- [Biotechnology Investors in France](https://shizune.co/investors/biotechnology-investors-france)
- [Biotechnology VC Funds in France](https://shizune.co/investors/biotechnology-vc-funds-france)

## FAQ

### What does Angels Santé invest in?

Angels Santé invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Seed and Funding Round stage. Most of the 37 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Angels Santé's check size?

Angels Santé typically joins rounds of $1.1M–$4.6M at Seed and $658k–$1.3M at Angel. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Angels Santé participates in.

### How do I contact Angels Santé?

Public channels for Angels Santé include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Angels Santé?

The team at Angels Santé includes Guy-Charles Fanneau de la Horie (Co-founder), Patrick squiban (Executive) and Pierre-Emmanuel Aubert (Co-Founder and member of the board). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co